NCT05384873 (MURAL) is a NA clinical trial of Immunonutrition in Lung Cancer, Nonsmall Cell, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia.

Who is sponsoring NCT05384873?

NCT05384873 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia.

What drugs are being tested in NCT05384873?

Interventions in NCT05384873: Immunonutrition, Control dietary intervention.

What condition does NCT05384873 study?

NCT05384873 studies Lung Cancer, Nonsmall Cell.

Is NCT05384873 still recruiting?

NCT05384873 is currently recruiting now. Last updated 1 May 2025.

Last reviewed 2025-05-01 · How we verify

NCT05384873: MURAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunonutrition for Improving the Efficacy of Immunotherapy in Patients With Metastatic Non-small Cell Lung Cancer

Recruiting now NA Last updated 1 May 2025

What this trial tests

NA trial testing Immunonutrition in Lung Cancer, Nonsmall Cell in 180 participants. Currently enrolling.

Timeline

1 June 2023

Primary endpoint
31 July 2026

31 July 2027

Quick facts

Lead sponsor	Fondazione IRCCS Policlinico San Matteo di Pavia
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	180
Start date	1 June 2023
Primary completion	31 July 2026
Estimated completion	31 July 2027
Sites	1 location across Italy

Drugs / interventions tested

Immunonutrition — full drug profile →
Control dietary intervention

Conditions studied

Lung Cancer, Nonsmall Cell — all drugs for Lung Cancer, Nonsmall Cell →

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Who can join

18 and older, any sex, with Lung Cancer, Nonsmall Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study was designed to evaluate the efficacy of the early systematic provision of oral nutritional supplements enriched in immunonutrients in non-small lung cancer patients undergoing immunotherapy and receiving nutritional counseling

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy.
Kang X, Lau HC, Yu J. · · 2024 · cited 65× · PMID 38631285 · DOI 10.1016/j.xcrm.2024.101478
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions.
Kiousi DE, Kouroutzidou AZ, Neanidis K, Karavanis E, et al · · 2023 · cited 29× · PMID 37046762 · DOI 10.3390/cancers15072101
Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y, Liu CG, Zang D, Chen J. · · 2024 · cited 20× · PMID 38361936 · DOI 10.3389/fimmu.2024.1343450
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer.
Duttagupta S, Hakozaki T, Routy B, Messaoudene M. · · 2023 · cited 20× · PMID 37999101 · DOI 10.3390/curroncol30110681
Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling.
Caccialanza R, Cereda E, Agustoni F, Klersy C, et al · · 2022 · cited 10× · PMID 36434615 · DOI 10.1186/s12885-022-10296-x
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Boesch M, Baty F, Rassouli F, Kowatsch T, et al · · 2023 · cited 8× · PMID 37791231 · DOI 10.1080/2162402x.2023.2255459
Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?
Mattavelli E, Agustoni F, Tartara A, De Simeis F, et al · · 2025 · cited 3× · PMID 40927712 · DOI 10.3389/fimmu.2025.1612567
Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells.
Hilakivi-Clarke L, Verma V, McDermott M, Koak P, et al · · 2022 · cited 1× · PMID 41852822 · DOI 10.3389/frmbi.2022.1049688

Verify or expand the search:

Other trials of Immunonutrition

Trials testing the same drug.

NCT07395635 — Phase II Trial of Immunonutrition in Hepatectomy · NA · recruiting
NCT06103526 — Immunonutrition in ERAS Protocols in Gynecologic Oncology · NA · unknown
NCT05069402 — Impact of Various Diets on Surgical Complications · NA · completed
NCT05068882 — Impact of Oral Diets on Postoperative Fluid Collection · NA · unknown
NCT04611113 — Immunonutrition and Tolerance to Chemoradiotherapy in Patients With Head-neck Cancer · NA · recruiting

Other recruiting trials for Lung Cancer, Nonsmall Cell

Currently open trials in the same condition.

NCT06996249 — Prospective Data Collection Initiative on Thoracic Malignancies · recruiting
NCT06426511 — ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC · Phase 2 · recruiting
NCT06667154 — Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy · Phase 2 · recruiting
NCT05537922 — I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy · recruiting
NCT05085028 — A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Pat · Phase 3 · recruiting

Other Fondazione IRCCS Policlinico San Matteo di Pavia trials

Trials by the same sponsor.

NCT07534007 — Comprehensive Characterization of Immune Response Induced by Adjuvanted Glycoprotein E (gE)-Based Recombinant VAccine Zo · recruiting
NCT07494344 — Italian Retrospective/Prospective Observational Study on Prosthetic Surgery in Patients With Congenital Coagulation Dise · recruiting
NCT07356583 — Neonatal Enterovirus Infections in Italy: Virological Characterization, Genomic and Clinical-epidemiological Insights on · recruiting
NCT07435207 — Thrombotic RIsk FActors in AL-goneurodystrophy · enrolling by invitation
NCT07263802 — Effect of a Food Supplement on Glycemic Parameters in Patients With Impaired Glucose Metabolism · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05384873 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondazione IRCCS Policlinico San Matteo di Pavia
Last refreshed: 1 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05384873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing